Bradykinin metabolism and hypotensive transfusion reactions

Transfusion

Volumn 41, Issue 1, 2001, Pages 136-150

  Cyr, Melanie ^a   Eastlund, Ted ^a   Blais Jr , Charles ^a   Rouleau, Jean Lucien ^a   Adam, Albert ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BRADYKININ; BRADYKININ RECEPTOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ICATIBANT; KININ DERIVATIVE;

APHERESIS; BLOOD FILTRATION; BLOOD TRANSFUSION; BLOOD TRANSFUSION REACTION; DRUG INDUCED DISEASE; DRUG MECHANISM; HUMAN; HYPERTENSION; KALLIKREIN KININ SYSTEM; REVIEW;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BLOOD TRANSFUSION; BRADYKININ; HUMANS; HYPOTENSION; KALLIKREINS; KININS;

EID: 0035125638     PISSN: 00411132     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1537-2995.2001.41010136.x     Document Type: Review

References (147)

1. Bioregulation of kinins: Kallikreins, kininogens, and kininases
2. Identification of prekallikrein and high-molecular-weight kininogen as a complex in human plasma
3. Gene structure and chromosomal localization of plasma kallikrein
4. Human plasma prekallikrein, a zymogen to a serine protease that contains four tandem repeats
5. Amino acid sequence of human factor XI, a blood coagulation factor with four tandem repeats that are highly homologous with plasma prekallikrein
6. Hageman factor substrates. Human plasma prekallikrein: Mechanism of activation by hageman factor and participation in Hageman factor-dependent fibrinolysis
7. Bradykinin formation. Plasma and tissue pathways and cellular interactions
8. The contact activation proteins: A structure/function overview
9. The coagulation-kinin pathway of human plasma
10. The molecular biology of the kallikrein-kinin system: III. The human kallikrein gene family and kallikrein substrate
11. The human kallikrein gene family: A diversity of expression and function
12. Kallikreins and kinins. Molecular characteristics and cellular and tissue responses
13. Cellular localization of human kininogens
14. Kininogens revisited
15. Contact system: A vascular biology modulator with anticoagulant, profibrinolytic, antiadhesive, and proinflammatory attributes
16. Gene expression, regulation and cell surface presentation of the kininogens
17. Structure and functions of human kininogens
18. Bradykinin formation in allergic diseases and hereditary angioedema
19. Association of factor XI and high molecular weight kininogen in human plasma
20. The expression of high molecular weight kininogen on human umbilical vein endothelial cells
21. The binding of high molecular weight kininogen to cultured human endothelial cells
22. Human neutrophils contain and bind high molecular weight kininogen
23. High molecular weight kininogen binds to unstimulated platelets
24. Identification of the zinc-dependent endothelial cell binding protein for high molecular weight kininogen and factor XII: Identity with the receptor that binds to the globular "head" of Clq (gC1q-R)
25. Cytokeratin 1 and gC1qR mediate high molecular weight kininogen binding to endothelial cells
26. Binding of high molecular weight kininogen to human endothelial cells is mediated via a site within domains 2 and 3 of the urokinase receptor
27. Immunovisualization of high (HK) and low (LK) molecular weight kininogens on isolated human neutrophils
28. High molecular weight kininogen binds to Mac-1 on neutrophils by its heavy chain (domain 3) and its light chain (domain 5)
29. Human kininogens regulate thrombin binding to platelets through the glycoprotein Ib-IX-V complex
30. Identification of cytokeratin 1 as a binding protein and presentation receptor for kininogens on endothelial cells
31. Human Hageman factor (factor XII) and high molecular weight kininogen compete for the same binding site on human umbilical vein endothelial cells
32. High molecular weight kininogen regulates prekallikrein assembly and activation on endothelial cells: A novel mechanism for contact activation
33. 1 receptors for kinins
34. Pharmacology of bradykinin and related kinins
35. 1 receptors: A review
36. Local regulation of vascular tone by bradykinin and angiotensin converting enzyme inhibitors
37. Kinins and endothelial control of vascular smooth muscle
38. Salt-sensitive hypertension in bradykinin B2 receptor knockout mice
39. Cardiovascular phenotype of a mouse strain with disruption of bradykinin B2-receptor gene
40. Metabolism of bradykinin by peptidases in health and disease
41. Two putative active centers in human angiotensin I-converting enzyme revealed by molecular cloning
42. Differences in the properties and enzymatic specificities of the two active sites of angiotensin I-converting enzyme (kininase II). Studies with bradykinin and other natural peptides
43. Catalytic properties of the two active sites of angiotensin I-converting enzyme on the cell surface
44. Tripeptidyl carboxypeptidase activity of kininase II (angiotensin-converting enzyme)
45. Cleavage of des-Arg9-bradykinin by angiotensin I-converting enzyme from pig kidney cortex
46. Substrate specificity and kinetic characteristics of angiotensin converting enzyme
47. Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects
48. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels
49. Angiotensin-converting enzyme gene polymorphism and cardiovascular disease
50. Polymorphism of the angiotensin-converting enzyme gene and cardiovascular disease
51. The common acute lymphoblastic leukemia antigen maps to chromosomal region 3 (q21-q27)
52. The common acute lymphoblastic leukemia antigen (neutral endopeptidase-3.4.24.11) gene is located on human chromosome 3
53. Some old and some new ideas on kinin metabolism
54. Insights into the structure and function of membrane polypeptides carrying blood group antigens
55. Proteolytic processing of big endothelin-3 by the Kell blood group protein
56. Novel activity of endothelin-converting enzyme: Hydrolysis of bradykinin
57. Neutral endopeptidase 24.11 in human neutrophils: Cleavage of chemotactic peptide
58. Molecular cloning of the common acute lymphoblastic leukemia antigen (CALLA) identifies a type II integral membrane protein
59. Basic carboxypeptidases: Regulators of peptide hormone activity
60. Cloning and tissue distribution of human membrane-bound aminopeptidase P
61. Cloning and functional expression of the cytoplasmic form of rat aminopeptidase P
62. Purification and characterization of pig kidney aminopeptidase P. A glycosylphosphatidylinositol-anchored ectoenzyme
63. Membrane-bound aminopeptidase P from bovine lung. Its purification, properties, and degradation of bradykinin
64. Development of digoxigenin-labeled peptide: Application to chemiluminoenzyme immunoassay of bradykinin in inflamed tissues
65. Quantification of des-Arg9-bradykinin using a chemiluminescence enzyme immunoassay: Application to its kinetic profile during plasma activation
66. Serum interspecies differences in metabolic pathways of bradykinin and [des-Arg9]BK: Influence of enalaprilat
67. Assay of dipeptidyl peptidase IV in serum by fluorometry of 4-methoxy-2-naphthylamine
68. The kallikreinkininogen-kinin system: Lessons from the quantification of endogenous kinins
69. Converting enzyme inhibitors
70. Converting enzyme inhibitors in cardiovascular therapy: Current status and future potential
71. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors
72. Enhancement of cytosolic calcium, prostacyclin and nitric oxyde by bradykinin and the ACE inhibitor ramiprilat in porcine brain capillary endothelial cells
73. Endothelial protection by converting enzyme inhibitors
74. Cardioprotective effect of angiotensin-converting enzyme inhibition against hypoxia/reoxygenation injury in cultured rat cardiac myocytes
75. Local inhibition of bradykinin degradation in ischemic hearts
76. Protective effects of bradykinin on the ischaemic heart: Implication of the B1 receptor
77. Ramiprilat increases bradykinin outflow from isolated hearts of rat
78. Effect of enalaprilat on bradykinin and des-Arg9-bradykinin release following reperfusion of the ischaemic rat heart
79. Bradykinin stimulates tissue plasminogen activator release in human vasculature
80. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis
81. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II. Evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function
82. The role of hyperglycaemia and hyperinsulinaemia in causing vascular dysfunction in diabetes
83. Diabetes mellitus and associated hypertension, vascular disease, and nephropathy. An update
84. Effects of captopril and Icatibant on bradykinin (BK) and des[Arg9]BK in carrageenan-induced edema
85. Absence of effect of chronic angiotensin II type 1 receptor blockade on endogenous kinin concentrations in the carrageenan-induced paw edema model in the rat
86. Involvement of endogenous kinins in the pathogenesis of peptidoglyca-induced arthritis in the Lewis rat
87. 2 receptor antagonists, des-Arg9,[Leu8]-BK and Hoe 140, in two models of persistent hyperalgesia in the rat
88. Concentration-dependent effects of bradykinin on leukocyte recruitment and venular hemodynamics in rat mesentery
89. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology
90. Plasma bradykinin in angio-oedema
91. Angioedema: Manifestations and management
92. Angiotensin-converting enzyme (ACE) inhibitors and angio-oedema
93. Angioedema: The role of ACE inhibitors and factors associated with poor clinical outcome
94. Serum metabolism of bradykinin and des-Arg9-bradykinin in patients with angiotensin-converting enzyme inhibitor-associated angioedema
95. Incidence of hypersensitivity in hemodialysis
96. First-use reactions during hemodialysis: A definition of subtypes
97. Des-Arg9-bradykinin metabolism in patients who presented hypersensitivity reactions during hemodialysis: Role of serum ACE and aminopeptidase P
98. Hypotension associated with prekallikrein activation (Hageman-factor fragments) in plasma protein fraction
99. Bradykinin-mediated hypotension after infusion of plasma-protein fraction
100. Correlation of hypotensive effect of plasma protein fraction with prekallikrein activator activity: A clinical study in patients having open-heart surgery
101. Cardiopulmonary bypass increases plasma bradykinin concentrations
102. Low-density lipoprotein apheresis for prevention and regression of atherosclerosis
103. Anaphylactoid reactions, LDL apheresis with dextran sulphate, and ACE inhibitors
104. ACE inhibitors and LDL-apheresis with dextran sulphate adsorption
105. Anaphylactoid reactions and bradykinin generation in patients treated with LDL-apheresis and ACE inhibitor
106. LDL-apheresis with dextran sulphate and anaphylactoid reactions to ACE inhibitors
107. LDL-apheresis and concomitant ACE-inhibitor therapy
108. Changes in bradykinin and prostaglandin plasma levels during dextran-sulfate low-density-lipoprotein apheresis
109. Plasma constituents other than low-density lipoprotein adsorbed by dext-ran-sulfate column
110. LDL apheresis with dextran sulfate and angiotensin receptor antagonist (Losartan)
111. Hypotension during sham apheresis in a patient taking ACE inhibitors
112. Effect of nafamostat mesilate on bradykinin generation during low-density lipoprotein apheresis using a dextran sulfate cellulose column
113. Cryofiltration apheresis and plasma fractionation causing anaphylactoid reactions in patients receiving angiotensin converting enzyme inhibitors
114. Elevated bradykinin and decreased carboxypeptidase R as a cause of hypotension during tryptophan column immunoabsorption therapy
115. Apheresis and ACE inhibitors
116. Atypical reactions associated with use of angiotensin-converting enzyme inhibitors and apheresis
117. Hypotension and bedside leukoreduction filters
118. Adverse reactions to platelet transfusions reported
119. Hypotensive reactions to white cell-reduced plasma in a patient undergoing angiotensin-converting enzyme inhibitor therapy
120. Hypotensive reactions: A previously uncharacterized complication of platelet transfusion?
121. Hypotensive reactions associated with platelet transfusions and angiotensin-converting enzyme inhibitors
122. Anomaly of the desArg9-bradykinin metabolism associated with severe hypotensive reactions during blood transfusions: A preliminary study
123. Anaphylaxis associated with white-cell reduction filter
124. Association between angiotensin-converting enzyme (ACE) inhibitors and hypotensive transfusion reactions
125. Kinetics of bradykinin levels during and after leucocyte filtration of platelet concentrates
126. Bradykinin formation in a platelet concentrate filtered with a leukocyte-removal filter made of nonwoven polyester fibers with a negatively charged surface
127. Bradykinin generation during filtration of platelet concentrates with a white cell-reduction filter
128. Bradykinin generation in red cell concentrates filtered with leukocyte-removal filters
129. Quality of platelet components: The role of suspension medium and leukocyte depletion
130. More on kininogen measurements in platelet concentrates that are white cell (WBC) reduced with WBC-reduction filters
131. Hypotension reactions during transfusion: Is bradykinin the culprit?
132. Lack of clinically significant contact system activation during platelet concentrate filtration by leukocyte removal filters
133. Cleavage of high molecular weight kininogen induced by filtration of platelet concentrates
134. Activation of the contact system by filtration of platelet concentrates with a negatively charged white cell-removal filter and measurement of venous blood bradykinin level in patients who received filtered platelets
135. Hypotensive reactions with a white cell-reduction filter: Activation of kallikrein-kinin cascade in a patient
136. Hypotensive reactions to red cells filtered at the bedside, but not to those filtered before storage, in patients taking ACE inhibitors
137. Hypotensive reactions during transfusion: Is bradykinin the culprit?
138. Bradykinin generation in RC-MAP during storage at 4°C and leukocyte removal filtration
139. Infusion site pain related to bedside white cell-reduction filters
140. Hypotensive reactions during platelet transfusions
141. Hypotensive reactions: Are they a new phenomenon? Are they related solely to transfusion of platelets? Does filtration of components play a role?
142. Hypotensive reactions associated with white cell-reduced apheresis platelet concentrates in patients not receiving ACE inhibitors
143. Ex vivo factors affecting contact phase activation in negatively charged medical devices
144. Anion-blood contact (ABC reaction) in patients treated by LDL apheresis with dextran sulfate-cellulose column while receiving ACE inhibitors
145. Biologic activities of the contact factors in vivo - Potentiation of hypotension, inflammation, and fibrinolysis, and inhibition of cell adhesion, angiogenesis and thrombosis
146. Prevention with icatibant of anaphylactoid reactions to ACE inhibitor during LDL apheresis
147. Les substances hypotensives de l'urine humaine normale